RS
CNTA

R Squared’s Centessa Pharmaceuticals CNTA Stock Holding History

R Squared’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-990
Closed -$16.6K – 550
2024
Q4 		$16.6K Buy
+990
New +$16.4K 0.02% 962

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

R Squared's CNTA Position: Q1 2025 in Review

R Squared sold out of Centessa Pharmaceuticals (CNTA) in Q1 2025, closing a stake of 990 shares — an estimated $16.6K sold.

R Squared first reported a position in CNTA in Q4 2024 and held it in 1 quarter. The position peaked at $16.6K in Q4 2024. 129 funds tracked by Wall St. Rank hold CNTA as of Q1 2025.

  • R Squared reported no remaining Centessa Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • R Squared sold 990 Centessa Pharmaceuticals shares in Q1 2025, an estimated $16.6K.
  • R Squared first reported a position in Centessa Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • R Squared's Centessa Pharmaceuticals position peaked at $16.6K in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.